Aclaris Therapeutics Inc (NASDAQ: ACRS) Could Achieve Gains In The Near Future

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

Aclaris Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Diagnostics & Research industry. The current market capitalization of Aclaris Therapeutics Inc is $87.94M. A total of 0.6 million shares were traded on the day, compared to an average of 1.77M shares.

In the most recent transaction, Powell Andrew Kenneth William bought 6,000 shares of ACRS for 1.25 per share on Mar 04 ’24. After the transaction, the Director now owns 28,863 company shares. In a previous transaction on Mar 01 ’24, Powell Andrew Kenneth William bought 8,500 shares at 1.23 per share. ACRS shares that Director owns now total 22,863.

Among the insiders who sold shares, Monahan Joseph disposed of 6,000 shares on Oct 23 ’23 at a per-share price of $5.08. This resulted in the Chief Scientific Officer holding 129,724 shares of ACRS after the transaction. In another insider transaction, Balthaser Kevin bought 9,490 shares at $7.90 per share on Sep 06 ’23. Company shares held by the Chief Financial Officer now total 15,461.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ACRS has a high of $11.12 and a low of $0.59.

As of this writing, ACRS has an earnings estimate of -$0.29 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.08 per share and a lower estimate of -$0.37. The company reported an EPS of -$0.41 in the last quarter, which was 14.60% higher than expectations of -$0.48.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ACRS’s latest balance sheet shows that the firm has $191.41M in Cash & Short Term Investments as of fiscal 2021. There were $693.00k in debt and $22.93M in liabilities at the time. Its Book Value Per Share was $2.22, while its Total Shareholder’s Equity was $197.34M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACRS is Buy with a score of 3.22.

Most Popular

Related Posts